Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics (INTI) shows no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, indicating a stable recent period on the governance front. However, absence of near-term signals does not rule out structural risks—the company operates in a capital-intensive biotech sector where equity dilution, financing patterns, and cash runway merit deeper analysis. Our 90-day window captures only recent snapshots; material events may have occurred in the preceding nine months. The full $49 Report adds a 12-month event timeline, dilution risk scoring, complete financing history, and AI-detected risk signals across SEC filings and officer transactions.